ADPKD Treatment Report

www.ADPKDTreatmentReport.com

News

Palladio Completes $20 Million Series B Financing: Proceeds will support development of lixivaptan, a potential treatment for ADPKD

https://www.businesswire.com/news/home/20200925005062/en/Palladio-Completes-20-Million-Series-B-Financing

Palladio Completes $20 Million Series B Financing: Proceeds will support development of lixivaptan, a potential treatment for ADPKD

Palladio Completes $20 Million Series B Financing
— Led by Samsara BioCapital
— Advancing Phase 3 ALERT Study

September 25, 2020 06:09 AM Eastern Daylight Time
HORSHAM, Pa.–(BUSINESS WIRE)–Palladio Biosciences, Inc. (Palladio), a privately-held, clinical stage biopharmaceutical company developing medicines for orphan diseases of the kidney, announced today the completion of a $20 million Series B investment. The financing was led by new investor, Samsara BioCapital, with participation from new investor, the Roche Venture Fund and existing investors, Medicxi and Osage University Partners. Proceeds from the financing will fund Palladio’s Phase 3 ALERT Study and advance operations.

“We are very pleased that Samsara and the Roche Venture Fund recognize the opportunity lixivaptan represents to patients suffering from ADPKD, and we are glad to be working with these new partners to further develop this important therapy”

Tweet this
Srinivas Akkaraju M.D, Ph.D, Managing General Partner of Samsara BioCapital, stated, “We are very excited about our investment in Palladio to support the development of lixivaptan, a drug that has the potential to deliver a meaningful therapeutic advancement in the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The ALERT Study is an important step in assessing the safety differential of lixivaptan.”

“We are very pleased that Samsara and the Roche Venture Fund recognize the opportunity lixivaptan represents to patients suffering from ADPKD, and we are glad to be working with these new partners to further develop this important therapy,” said Francesco De Rubertis, co-founder and Partner at Medicxi.

Reproducing the pathophysiology of polycystic kidney disease from human iPS cells: Understanding the pathogenesis of ADPKD and developing new treatments

https://www.sciencedaily.com/releases/2020/08/200821094825.htm

Reproducing the pathophysiology of polycystic kidney disease from human iPS cells
Understanding the pathogenesis of hereditary polycystic kidney disease and developing new treatments
Date:
August 21, 2020
Source:
Kumamoto University
Summary:
A research project has successfully reproduced the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD) from human iPS cells in vitro. Although cysts derived from renal tubules have been previously documented, this is the first derivation of cysts from collecting ducts, which is more closely related to the pathogenesis of the disease. This research is expected to lead to a better understanding of disease states and the development of new treatment methods.
Share:

FULL STORY
Joint research, led by Kumamoto University in Japan, has successfully reproduced the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD) from human iPS cells in vitro. ADPKD is a disease that causes multiple cysts in both kidneys and is the most common hereditary kidney disease. Although cysts derived from renal tubules have been previously documented, this is the first induction of cysts from collecting ducts, which is more closely related to the pathogenesis of the disease. The researchers expect that this will lead to a better understanding of disease states and the development of new treatment methods.

An affordable and commonly used diabetes drug is being touted as a potential treatment for ADPKD

https://www.uq.edu.au/news/article/2020/07/diabetes-drug-could-prevent-kidney-failure

An affordable and commonly used diabetes drug is being touted as a potential treatment, for a rare form of kidney disease

Diabetes drug could prevent kidney failure

30 July 2020
An affordable diabetes drug could save generations of Australian families who live with polycystic kidney disease from kidney failure.

FDA has granted Regulus Therapeutics orphan drug designation for RGLS4326, an investigational therapy being studied to treat ADPKD

https://www.ajmc.com/view/fda-grants-orphan-drug-status-to-regulus-therapeutics-treatment-for-common-type-of-pkd

DA Grants Orphan Drug Status to Regulus Therapeutics’ Treatment for Common Type of PKD
July 29, 2020
Mary Caffrey

Although the name suggests the disease affects only the kidneys, development of fluid-filled cysts can spread to the liver, the pancreas, and other organs. While a healthy kidney is about the size of a fist, a kidney filled with cysts from polycystic kidney disease (PKD) can grow to be about the size of a football weigh up to 30 pounds

Regulus Therapeutics announced today FDA has granted the company orphan drug designation for RGLS4326, an investigational therapy being studied to treat autosomal dominant polycystic kidney disease (ADPKD), the most common type of a group of genetic disorders that lead to end-stage renal disease, morbidity, and early death.

XORTX Provides Overview and Update of Key Activities – Including Update on XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

https://www.globenewswire.com/news-release/2020/04/30/2025227/0/en/XORTX-Provides-Overview-and-Update-of-Key-Activities.html

XORTX Provides Overview and Update of Key Activities

The following summarizes the advancements made in 2019 to date in XORTX’s three programs:

XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD):

Growing outreach to key polycystic disease physicians and patient advocacy groups to advance the XRx-008 program toward a phase 3 registration trial;

XRX-008 program further validated by evidence of a new mechanism of injury in polycystic kidney disease, this study showed that uric acid and oxalate crystals may play a key role in the initiation of new kidney cysts and accelerating the growth of those cysts as well as in the generation of kidney stones in individuals with ADPKD;

Advanced Orphan Drug Designation (“ODD”) documents for completion of filing with the FDA for XRx-008 for the treatment of progressive kidney disease due to ADPKD;

Introduced Dr. Anjay Rastogi, UCLA to XORTX’s Clinical Advisory Board; and

Initiated and ongoing discussions with pharmaceutical company partners for this program.

PKD Foundation Receives $9.3 Million Donation – 100 percent of gift is designated to research and finding a cure for PKD

Trust of Alfred Busiel donates over 9-million

FOR IMMEDIATE RELEASE:

PKD Foundation Receives $9.3 Million Donation from the Trust of Alfred Busiel, Former Owner of Lady Esther Cosmetics
This Generous Donation is an Important Step in Reaching a $70 Million Campaign Goal over the Next Five Years
KANSAS CITY, Mo. — The PKD Foundation is pleased to announce the generous gift of a donation in the amount of $9.3 million from the trust of Alfred Busiel, former owner of the cosmetic company, Lady Esther.

Based in Kansas City, Mo., the PKD Foundation is the only organization in the United States solely dedicated to funding critical research and finding a cure for polycystic kidney disease (PKD).

Exactly 100 Percent of Busiel’s Donation to Support PKD Research
This significant commitment from Busiel allows the PKD Foundation to support its Future Focus Campaign, a campaign with a five-year goal to raise $70 million to increase the Foundation’s commitment to PKD research by 300 percent.

Exactly 100 percent of Busiel’s gift is designated to research and directly supports the PKD Foundation’s vision to end PKD.

“We are very fortunate to receive this generous donation from Mr. Busiel. This is a critical milestone in helping us achieve our Future Focus Campaign goal. Now, the Foundation only needs to raise approximately $5 million more to reach our total goal,” Andy Betts, President and CEO of the PKD Foundation said. “With generous gifts such as Mr. Busiel’s, we can spend a significant amount of our resources on doing what’s most important – focusing on new research, which is vital to making progressive strides in treatment research and to support finding a cure – our ultimate goal.”

New drug compound could tackle major life-limiting kidney disease (ADPKD)

https://www.sciencedaily.com/releases/2019/06/190618103723.htm

New drug compound could tackle major life-limiting kidney disease
Date:
June 18, 2019
Source:
University of Sheffield
Summary:
Scientists are developing a new class of drugs to treat a common genetic kidney disease which is a major cause of kidney failure.
Share:

FULL STORY
Scientists from the University of Sheffield are part of an international collaboration to develop a new class of drugs to treat a common genetic kidney disease which is a major cause of kidney failure.

Working with Glasgow-based biotech company Mironid and colleagues in the US, the Sheffield researchers have carried out successful laboratory tests of a compound developed by Mironid to treat autosomal dominant polycystic kidney disease (ADPKD), a hereditary, progressive disease which affects over 60,000 people in the UK and around 12 million people worldwide.

Back to top